Ensysce Biosciences (ENSC) Stock
Ensysce Biosciences Chart
Company Profile
Price: $3.90
Market Cap: $5.48M
Exchange: NASDAQ
CEO: Dr. D. Lynn Kirkpatrick Ph.D.
Sector: Healthcare
Industry: Biotechnology
Employees: 7
Headquarters: La Jolla, CA
Website: Ensysce Biosciences
Business Summary
Ensysce Biosciences, Inc., a clinical-stage pharmaceutical company, engages in developing various prescription drugs for severe pain relief in opioid addiction, misuse, abuse, and overdose in the United States. It develops products using Trypsin Activated Abuse Protection platform, an abuse-resistant opioid prodrug technology; and Multi-Pill Abuse Resistance platform, an over-dose protection opioid prodrug technology. The company is developing PF614, a TAAP prodrug candidate of oxycodone, which is in Phase II clinical trial for the treatment of acute or chronic pain; and PF614-MPAR, a combination product of PF614 and nafamostat that is in Phase I clinical trial for overdose protection against excessive oral ingestion, as well as an oral and inhalation drug product of nafamostat for use against coronaviral infections and other pulmonary diseases, such as cystic fibrosis. It is also developing PF329, an extended-release prodrug of hydromorphone that is similar to PF614; PF8001 and PF8026 are extended and immediate-release prodrugs of amphetamine for ADHD medication abuse; and PF26810, an extended-release prodrug of methadone for opioid use disorder. The company is based in La Jolla, California.
Ensysce Biosciences News
Ensysce Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results
Secures Strategic Partnership for the Development and Commercial Launch of PF614 and PF614-MPAR Groundbreaking Trial on PF614-MPAR Generates Positive Interim Results SAN DIEGO, CA / ACCESS Newswire / March 10, 2025 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical-stage pharmaceutical company developing innovative solutions for severe pain relief while reducing the potential for opioid abuse and overdose, today reported financial and operational results for the fourth quarter and full year ended December 31, 2024. Dr. Lynn Kirkpatrick, Chief Executive Officer of Ensysce, commented, "Our team continued to make significant strides in the fourth quarter to deliver what we believe are the ‘Next Generation' opioid analgesics with both abuse and overdose protection.
Ensysce Biosciences to Participate in the 37th Annual ROTH Conference
SAN DIEGO, CA / ACCESS Newswire / March 5, 2025 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical-stage pharmaceutical company developing innovative solutions for severe pain relief while reducing the potential for opioid abuse and overdose, today announced its participation in the 37th Annual ROTH Conference being held Sunday, March 16th to Tuesday, March 18th at the Laguna Cliffs Marriott Resort in Dana Point, CA. Ensysce's Chief Executive Officer Dr. Lynn Kirkpatrick, Chief Financial Officer Dave Humphrey, and Chief Commercial Officer Geoff Birkett will be available to host one-on-one meetings with investors during the event.
Ensysce Biosciences CEO Dr. Lynn Kirkpatrick and Creighton University's Dr. Neel Pathak Discuss the Opioid Crisis and Next Generation Opioids
NEW YORK , March 3, 2025 /PRNewswire/ -- Today's Marketplace (TMP) is proud to announce a featured interview with Ensysce Biosciences (NASDAQ: ENSC) CEO Dr. Lynn Kirkpatrick and Dr. Neel Pathak, DS , Program Director with Creighton University . The doctors joined TMP's host Jane King to discuss the ongoing issues with opioids for pain management and how "clever chemistry" is being used to introduce safer opioids that are less prone to accidental overdose and abuse.
Ensysce Biosciences Reports Continued Positive Progress in Groundbreaking Trial on PF614-MPAR, Comments on Current Landscape for Pain Treatment
~ Positive Enrollment Progress and Safety Data ~ ~ FDA Attention Establishes Momentum in the Pain Treatment Space ~ SAN DIEGO, CA / ACCESS Newswire / February 5, 2025 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical-stage pharmaceutical company developing innovative solutions for severe pain relief while reducing the potential for opioid abuse and overdose, today announced continued subject enrollment and successful dosing augmenting the progress of its second clinical trial to evaluate PF614-MPAR for overdose protection. In the current study of PF614-MPAR-102, data showed that a 100 mg dosage form of PF614-MPAR provides overdose protection when a greater-than-prescribed dose is consumed at one time.
Ensysce Biosciences Announces Positive Interim Data for Breakthrough Therapy PF614-MPAR
~ Positive Phase 1b Data Confirms Overdose Protection for Highest Dosage Form of PF614-MPAR ~ SAN DIEGO, CA / ACCESS Newswire / January 22, 2025 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical-stage pharmaceutical company developing innovative solutions for severe pain relief while reducing the potential for opioid abuse and overdose, today announced interim data from its second clinical trial to evaluate PF614-MPAR for overdose protection. Clinical study PF614-MPAR-102, ‘A Single and Multiple Dose Study to Evaluate the Pharmacokinetics of Oxycodone and PF614 when PF614 Capsule is Co‑Administered with Nafamostat as a Combination of Immediate Release Solution and Extended Release Capsule Formulations (PF614-MPAR) in Healthy Subjects,' was designed to evaluate the full dosage range of PF614-MPAR, study potential food effects, and to conduct a multiple ascending dose study with the final PF614-MPAR combination.
Ensysce Biosciences Issues Annual Shareholder Letter
~ FDA Breakthrough Therapy designation received for PF614-MPAR ~ ~ PF614-MPAR second clinical trial initiated ~ ~ Lead clinical candidate identified for OUD program ~ ~ PF614 Phase 3 trial poised to commence 1H 2025 ~ SAN DIEGO, CA / ACCESSWIRE / January 8, 2025 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or "Company"), a clinical-stage pharmaceutical company developing innovative solutions for severe pain relief while reducing the potential for opioid abuse and overdose, today issued a letter to shareholders from Chief Executive Officer, Dr. Lynn Kirkpatrick. Dear Fellow Shareholders, 2024 was underscored by outstanding progress for our two clinical programs, and I would like to thank you and all of our committed shareholders for their support over the last year.
Ensysce Biosciences Regains Full Compliance with Nasdaq
SAN DIEGO, CALIFORNIA / ACCESSWIRE / December 23, 2024 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or "Company"), a clinical-stage pharmaceutical company developing innovative solutions for severe pain relief while reducing the potential for opioid abuse and overdose, today announced that on December 20, 2024, it received notice from The Nasdaq Stock Market LLC ("Nasdaq") that the Company has demonstrated compliance with the minimum bid price requirement in Listing Rule 5550(a)(2). Ensysce had previously regained compliance with the stockholders' equity requirement in Listing Rule 5550(b)(1).
Ensysce Biosciences Announces Commercial Supplier for Breakthrough Overdose Protection Drug Product
~ Supply Chain Now Fully Secure for PF614-MPAR ~ SAN DIEGO, CA / ACCESSWIRE / December 10, 2024 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or "Company"), a clinical-stage pharmaceutical company developing innovative solutions for severe pain relief while reducing the potential for opioid abuse and overdose, today announced the receipt of commitment of future supply of GMP nafamostat, a critical component of PF614-MPAR. This agreement fully secures the supply chain and allows Ensysce to reference the nafamostat Drug Master File of Aurore Life Sciences, a renowned specialty drug manufacturer.
Ensysce Biosciences Announces Strategic Partnership for the Development and Commercial Launch of PF614 and PF614-MPAR
~ $10 Million Commitment from Specialty Drug Manufacturer to Support Commercialization Efforts ~ SAN DIEGO, CA / ACCESSWIRE / December 4, 2024 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or "Company"), a clinical-stage pharmaceutical company developing innovative solutions for severe pain relief while reducing the potential for opioid abuse and overdose, today announced the initiation of a strategic partnership with a leading specialty drug manufacturer for the development and commercial launch of PF614 and PF614-MPAR drug products. This collaboration underscores a shared commitment to achieving swift regulatory approval and efficient development of the Company's innovative drug products.
Ensysce Biosciences Announces 1-for-15 Reverse Stock Split
SAN DIEGO, CA / ACCESSWIRE / December 3, 2024 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical-stage pharmaceutical company developing innovative solutions for severe pain relief while reducing the potential for opioid abuse and overdose, today announced that on Friday, December 6, 2024, effective at 12:01 a.m. Eastern Time, it will implement a 1-for-15 reverse split of its common stock.
Ensysce Biosciences Completes Significant Milestone, Dosing First Subjects in Breakthrough Therapy PF614-MPAR Trial
~ Landmark Overdose Protection Clinical Trial of PF614-MPAR ~ ~ Expects Early Interim Data in 1Q 2025 ~ SAN DIEGO, CA / ACCESSWIRE / November 26, 2024 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical-stage pharmaceutical company developing innovative solutions for severe pain relief while reducing the potential for opioid abuse and overdose, today announced that it has treated its first group of subjects in the PF614-MPAR-102 study. PF614-MPAR received Breakthrough Therapy designation from the U.S. Food and Drug Administration (FDA) and had its development bolstered by the recent $14 million multi-year award from the National Institute on Drug Abuse (NIDA).
Ensysce Biosciences Reports Third Quarter 2024 Financial Results
Awarded $14 Million Multi-Year NIH Grant and Initiated Second Clinical Trial for Breakthrough Therapy PF614-MPAR Submitted Pivotal PF614 Phase 3 Protocol to the FDA for Review SAN DIEGO, CA / ACCESSWIRE / November 12, 2024 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical-stage pharmaceutical company developing innovative solutions for severe pain relief while reducing the potential for opioid abuse and overdose, today reported financial and operational results for the third quarter ended September 30, 2024. Dr. Lynn Kirkpatrick, Chief Executive Officer of Ensysce, commented, "Our team has made significant progress in the third quarter, and we have line of sight to meaningful clinical initiatives to close out the year.
Ensysce Biosciences Receives Positive Nasdaq Listing Determination
SAN DIEGO, CA / ACCESSWIRE / November 7, 2024 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or "Company"), a clinical-stage pharmaceutical company developing innovative solutions for severe pain relief while reducing the potential for opioid abuse and overdose, today announced that it has received notice from The Nasdaq Stock Market ("Nasdaq") as described in a decision dated November 5, 2024, that the Company may continue its listing on The Nasdaq Capital Market tier with an extension to November 14, 2024, to demonstrate compliance with the equity requirement in Listing Rule 5550(b)(1) as of September 30, 2024, with filing of its Form 10-Q. Additionally, the Company received an extension toDecember 19, 2024, to evidence compliance with the Minimum Bid Price in Listing Rule 5550(a)(2), all other applicable requirements and the Company's satisfaction of certain other interim conditions.
Ensysce Biosciences Announces Leadership Team's Participation in the Annual Pain Therapeutics Summit
~ Dr. Lynn Kirkpatrick to Present Latest Clinical Data for PF614 and PF614-MPAR ~ ~ Dr. William Schmidt to Deliver Opening Remarks as Summit Chair ~ SAN DIEGO, CA / ACCESSWIRE / October 8, 2024 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or "Company"), a clinical-stage pharmaceutical company developing innovative solutions for severe pain relief while reducing the potential for opioid abuse and overdose, today announced that Dr. Lynn Kirkpatrick, Chief Executive Officer of Ensysce, will present at the 18th Annual Pain Therapeutics Summit taking place on October 28 and 29, 2024 in Boston, MA. Dr.
Ensysce Biosciences Provides Shareholder Update, Responds to Recent Shareholder Inquiries
SAN DIEGO, CA / ACCESSWIRE / October 2, 2024 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or "Company"), a clinical-stage pharmaceutical company developing innovative solutions for severe pain relief while reducing the potential for opioid abuse and overdose, today provides a response from Chief Executive Officer, Dr. Lynn Kirkpatrick, regarding recent inquiries from stockholders and other interested parties. Dear Fellow Stockholders, It is important to me to directly deliver an update to our supportive shareholders, stakeholders and partners, by addressing some questions we have recently received and providing a concise view of our development progress and timelines.
Ensysce Biosciences Receives Notice from Nasdaq
SAN DIEGO, CA / ACCESSWIRE / September 27, 2024 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or "Company"), a clinical-stage pharmaceutical company developing innovative solutions for severe pain relief while reducing the potential for opioid abuse and overdose, has received notice from the listing qualifications department staff of The Nasdaq Stock Market ("Nasdaq") stating that the Company has not regained compliance with Nasdaq Listing Rule 5550(a)(2) because the bid price for the Company's common stock has remained below $1.00 per share through the initial 180-day compliance period ended September 23, 2024. The Company is not eligible for a second 180-day period because it does not comply with the minimum stockholders' equity requirement for initial listing on The Nasdaq Capital Market.
Ensysce Biosciences Presenting at Upcoming Meetings
~ New Data on Opioid Use Disorder Program at Society for Neuroscience Meeting ~ ~ Ensysce CEO Invited Expert Speaker at Formulation & Delivery US 2024 Meeting ~ SAN DIEGO, CA / ACCESSWIRE / September 24, 2024 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical-stage pharmaceutical company developing innovative solutions for severe pain relief while reducing the potential for opioid abuse and overdose, today announced its participation in two upcoming meetings in October 2024. October 5, 2024: New data will be presented in a poster session in collaboration with Sygnature Discovery at the Society for Neuroscience meeting in Chicago in the session for Addictive Drugs: Drug Tolerance, Dependence, and Toxicity.The poster entitled "Methadone ameliorates the effects of morphine withdrawal in a modified rat model of physical dependence" is the first study of its kind in a pre-clinical model to evaluate the efficacy of novel agents for treating Opioid Use Disorder (OUD).OUD affects 16 million people worldwide and can be attributed to 500,000 deaths each year.
Ensysce Biosciences Submits Phase 3 Protocol to the FDA
Phase 3 Study to Assess PF614 Efficacy in Treating Post-Surgical Pain SAN DIEGO, CA / ACCESSWIRE / September 19, 2024 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical-stage pharmaceutical company developing innovative solutions for severe pain relief while reducing the potential for opioid abuse and overdose, today announced it has submitted to the FDA its PF614-301 protocol of the study, "A Multicenter, Randomized, Double-Blind, Placebo-and Active-Controlled Study to Evaluate the Efficacy and Safety of PF614 for the Treatment of Moderate to Severe Pain after Abdominoplasty". Included in the Phase 3 study is the Company's statistical analysis plan for review and input by the FDA.
Ensysce Biosciences Posts Video Updates from the IASP World Congress on Pain 2024
~ PF614 and PF614-MPAR Highlighted at Symposium on Severe Pain ~ SAN DIEGO, CA / ACCESSWIRE / September 13, 2024 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical-stage pharmaceutical company developing innovative solutions for severe pain relief while reducing the potential for opioid abuse and overdose, has made available two video segments from its August 8th symposium at the International Association for the Study of Pain (IASP) 2024 World Congress on Pain in Amsterdam, Netherlands. The Company's symposium emphasized opioid use worldwide, the current landscape for treating severe pain, including post-surgical and cancer pain treatment, and discussed Ensysce's innovative new class of opioid drug products.
Ensysce Biosciences, Inc. Announces $5 Million Concurrent Registered Direct Offering and Exercise of Warrants
SAN DIEGO, CA / ACCESSWIRE / August 29, 2024 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical-stage pharmaceutical company developing innovative solutions for severe pain relief while reducing the potential for opioid abuse and overdose, today announced that it has entered into definitive agreements, providing the Company with aggregate gross proceeds of $5 million, for the issuance and sale of an aggregate of 3,553,194 of its shares of common stock (or common stock equivalents in lieu thereof) at a purchase price of $0.47 per share (or common stock equivalent in lieu thereof) in a registered direct offering. The Company also entered into definitive agreements to exercise certain outstanding warrants to purchase up to an aggregate of 7,203,504 shares of common stock of the Company originally issued in February 2024, having an exercise price of $1.06 per share, at a reduced exercise price of $0.47 per share.
Ensysce Biosciences Announces IRB Approval for Key MPAR Study
Next Clinical Trial of FDA Breakthrough Therapy PF614-MPAR Supported by $14 Million Federal Government Grant SAN DIEGO, CA / ACCESSWIRE / August 27, 2024 / Ensysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ:ENSC), a clinical-stage pharmaceutical company developing innovative solutions for severe pain relief while reducing the potential for opioid abuse and overdose, today announced that it has received Investigational Review Board ("IRB") approval of the PF614-MPAR-102 protocol, ‘A Single and Multiple Dose Study to Evaluate the Pharmacokinetics of Oxycodone and PF614 when PF614 capsule is Co‑Administered with Nafamostat as a combination Immediate Release solution and Extended-Release Capsule Formulation in Healthy Subjects.' Ensysce has continued its collaboration with Quotient Sciences to conduct this second clinical study of MPAR using their Translational Pharmaceutics® platform.
Ensysce Biosciences Receives $14 Million NIH Grant for Clinical Development of Novel Opioid with Overdose Protection
~ Substantial Award Follows FDA Breakthrough Therapy Designation for PF614-MPAR ~ ~ Federal Grant Funding Awarded to Date Now at $40 Million ~ SAN DIEGO, CA / ACCESSWIRE / August 27, 2024 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical-stage pharmaceutical company developing innovative solutions for severe pain relief while reducing the potential for opioid abuse and overdose, today announced receipt of a $14 million multi-year grant from the NIH and National Institute on Drug Abuse (NIDA) for the continued development of PF614-MPAR, an abuse-deterrent opioid with overdose protection that received Breakthrough Therapy designation from the FDA in January 2024. Funding from this award will be available over a period of approximately three years, allowing for the completion of the Phase 1b clinical trial, PF614-MPAR-102.
Diamond Equity Research Releases Update Note on Ensysce Biosciences, Inc. (NASDAQ: ENSC)
NEW YORK, Aug. 23, 2024 (GLOBE NEWSWIRE) -- Diamond Equity Research, a leading equity research firm with a focus on small capitalization public companies has released an Update Note on Ensysce Biosciences, Inc. (NASDAQ: ENSC). The update note includes information on Ensysce Biosciences' business model, services, industry, financial results, valuation, and risks.
Ensysce Biosciences Reports Second Quarter 2024 Financial Results
PF614-MPAR Progressing to Phase 1b Study to Verify Both Overdose Protection and Effective Delivery of Oxycodone Opioid Use Disorder Program Advances with Selection of PF9001 as Lead Drug Candidate PF614 Phase 3 Protocol Being Finalized for Submission to FDA SAN DIEGO, CA / ACCESSWIRE / August 14, 2024 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical-stage pharmaceutical company developing innovative solutions for severe pain relief while reducing the potential for opioid abuse and overdose, today reported financial and operational results for the second quarter ended June 30, 2024. Dr. Lynn Kirkpatrick, Chief Executive Officer of Ensysce, commented, "Our FDA-designated Breakthrough Therapy product candidate, PF614-MPAR, is a game-changer for Ensysce as we progress to a second clinical trial, PF614-MPAR-102.
Ensysce Biosciences Provides Key Themes Following IASP 2024 Symposium
~ PF614 and PF614-MPAR Discussed in Satellite Symposium on Severe Pain ~ SAN DIEGO, CA / ACCESSWIRE / August 8, 2024 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical-stage pharmaceutical company developing innovative solutions for severe pain relief while reducing the potential for opioid abuse and overdose, provides a summary of its successful symposium at the International Association for the Study of Pain (IASP) 2024 World Congress on Pain in Amsterdam, Netherlands. The Company's symposium illustrated the current landscape of severe pain, including post-surgical and cancer pain treatment, and discussed potential innovative treatment options, noting the limited number of new therapeutic agents approved in the last ten years.
Ensysce Biosciences Provides Mid-Year 2024 Update
~ Ready to Commence PF614 Phase 3 Clinical Trial in 2024 ~ ~ Continued Clinical Development of Overdose Protection Breakthrough Therapy ~ ~ Identified Lead Clinical Candidate for Opioid Use Disorder Program ~ SAN DIEGO, CA / ACCESSWIRE / July 23, 2024 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical-stage pharmaceutical company developing innovative solutions for severe pain relief while reducing the potential for opioid abuse and overdose, today provides a Company review and update on a successful first half of 2024, including achievement of Breakthrough Therapy designation from the U.S. Food & Drug Administration (FDA). Recent clinical and development highlights: PF614: Successfully completed a PF614 End of Phase 2 meeting with the FDA, which provided guidance on strategy and design of the Phase 3 clinical program.
Ensysce Biosciences Hosts IASP 2024 Symposium and Presents Clinical Dataset
~ Dr. Lynn Kirkpatrick, CEO, to Introduce Satellite Symposium on Severe Pain: A New Chapter for Safer Analgesics ~ SAN DIEGO, CA / ACCESSWIRE / July 9, 2024 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical-stage pharmaceutical company developing innovative solutions for severe pain relief while reducing the potential for opioid abuse and overdose, today announced that the Company will host a symposium at the International Association for the Study of Pain (IASP) 2024 World Congress on Pain on August 8, 2024 in Amsterdam, Netherlands. The Symposium entitled: ‘Severe Pain: A New Chapter for Safer Analgesics' will feature Dr. Lars Arendt-Nielsen, Professor of Aalberg University of Medicine, Denmark, and Dr. William Schmidt, Chief Medical Officer of Ensysce Biosciences, two leading authorities on pain, pain treatment and analgesic drug development.
Ensysce Biosciences Discusses Key Themes from the EPHMRA 2024 Annual Meeting
~ Geoff Birkett, Chief Commercial Officer, Provides Insight Following EPHMRA Meeting ~ SAN DIEGO, CA / ACCESSWIRE / June 27, 2024 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical stage pharmaceutical company developing innovative solutions for severe pain relief while reducing the potential for opioid abuse and overdose, provides takeaways from Geoff Birkett, the Company's Chief Commercial Officer, following his participation on the opening panel of the European Pharmaceutical Market Research Association (EPHMRA) Annual Conference in London on June 25. Geoff Birkett discussed "The Future of Healthcare Research" with industry partners and underlined the importance of new healthcare technologies to address key problems for patients and the companies that serve them.
Ensysce Biosciences Announces Partnership to Scale and Manufacture New Drug Candidate
~ Collaboration with Purisys Positions Ensysce to Expedite Lead OUD Candidate, PF9001, to IND Studies ~ SAN DIEGO, CA / ACCESSWIRE / June 25, 2024 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical-stage pharmaceutical company developing innovative solutions for severe pain relief while reducing the potential for opioid abuse and overdose, today announced an agreement with Purisys LLC ("Purisys") to scale the manufacture of the Company's lead opioid use disorder (OUD) drug candidate. PF9001, as recently announced, is a novel agent developed with Ensysce's unique TAAP technology to treat OUD that will potentially decrease the cardiovascular side effects associated with methadone.
Ensysce Biosciences Announces Major Milestone for Opioid Use Disorder Program
~ Selects Lead Candidate with Abuse Deterrence and Improved Safety Profile to Treat Opioid Use Disorder ~ SAN DIEGO, CA / ACCESSWIRE / June 6, 2024 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical-stage pharmaceutical company developing innovative solutions for severe pain relief while reducing the potential for opioid misuse, abuse and overdose, today announced the achievement of a critical milestone in its opioid use disorder (OUD) program with the selection of a lead drug candidate to move into Investigational New Drug (IND) enabling studies. Designed with the application of Ensysce's TAAP platform to reduce the abuse profile, lead candidate PF9001 has shown lower potential for cardiovascular side effects associated with traditional methadone opioid use disorder (OUD) treatments.
Ensysce Biosciences Earnings
This section highlights Ensysce Biosciences's earnings, including key dates, EPS, earnings reports, and earnings call transcripts.
Next Earnings Date
Last Earnings Results
Earnings Call Transcripts
| Transcript | Quarter | Year | Date | Estimated EPS | Actual EPS |
|---|
Financial Statements
Access annual & quarterly financial statements for Ensysce Biosciences, including income statements, balance sheets, and cash flow statements..
Annual Income Statement
| Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Revenue | $- | $2.23M | $2.52M | $3.53M | $3.93M |
| Cost of Revenue | $- | $7.59M | $19.84M | $151 | $1.37M |
| Gross Profit | $- | $-5.36M | $-17.31M | $3.53M | $2.56M |
| Gross Profit Ratio | 0.00% | -240.17% | -686.08% | 100.00% | 65.18% |
| Research and Development Expenses | $7.22T | $7.59M | $19.84M | $4.69M | $4.39M |
| General and Administrative Expenses | $4.72T | $5.36M | $6.91M | $18.71M | $1.15M |
| Selling and Marketing Expenses | $- | $- | $- | $- | $- |
| Selling General and Administrative Expenses | $4.72T | $5.36M | $6.91M | $18.71M | $1.15M |
| Other Expenses | $- | $-7.59M | $-2.52M | $-3.53M | $-3.93M |
| Operating Expenses | $11.94T | $5.36M | $24.22M | $19.87M | $1.61M |
| Cost and Expenses | $- | $12.95M | $24.22M | $19.87M | $1.61M |
| Interest Income | $- | $- | $1.25M | $3.22M | $719.65K |
| Interest Expense | $-1.29T | $353.94K | $109.53K | $1.30M | $995.50K |
| Depreciation and Amortization | $- | $-3 | $151 | $151 | $201 |
| EBITDA | $-6.73T | $-10.72M | $-24.22M | $-19.87M | $-1.61M |
| EBITDA Ratio | 0.00% | -480.52% | -959.91% | -562.71% | -41.03% |
| Operating Income | $-6.73T | $-10.72M | $-24.22M | $-19.87M | $-1.61M |
| Operating Income Ratio | 0.00% | -480.52% | -959.91% | -562.71% | -41.04% |
| Total Other Income Expenses Net | $-1.26T | $91.91K | $14.41K | $-9.28M | $1.45M |
| Income Before Tax | $-7.99T | $-10.63M | $-24.21M | $-29.15M | $-160.88K |
| Income Before Tax Ratio | 0.00% | -476.40% | -959.33% | -825.38% | -4.09% |
| Income Tax Expense | $- | $- | $753.88K | $-151 | $777.85K |
| Net Income | $-7.99T | $-10.61M | $-24.96M | $-29.15M | $-938.73K |
| Net Income Ratio | 0.00% | -475.81% | -989.21% | -825.38% | -23.88% |
| EPS | $-11448.17 | $-4.69 | $-138.73 | $-346.90 | $-14.29 |
| EPS Diluted | $-11448.17 | $-4.69 | $-138.73 | $-346.90 | $-13.65 |
| Weighted Average Shares Outstanding | 697.69M | 2.26M | 179.93K | 84.02K | 65.70K |
| Weighted Average Shares Outstanding Diluted | 697.69M | 2.26M | 179.93K | 84.02K | 68.78K |
| SEC Filing | Source | Source | Source | Source | Source |
Income Statement Charts
| Breakdown | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 | December 31, 2019 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $- | $181.80K | $305.72K | $515.03K | $435.38K | $490.47K | $789.63K | $1.43M | $279.35K | $207.47K | $603.10K | $1.64M | $1.20M | $444.52K | $250.58K | $416.49K | $827.64K | $1.82M | $862.40K | $- |
| Cost of Revenue | $- | $947.23K | $- | $3.44M | $1.91M | $1.64M | $1.80M | $6.44M | $4.76M | $5.31M | $3.14M | $2.19M | $1.71M | $463.22K | $292.03K | $1.25M | $287.25K | $71.67K | $915.18K | $1.93M |
| Gross Profit | $- | $-765.43K | $305.72K | $-2.92M | $-1.48M | $-1.15M | $-1.01M | $-5.01M | $-4.48M | $-5.10M | $-2.54M | $-552.56K | $-513.82K | $-18.70K | $-41.45K | $-836.88K | $540.38K | $1.75M | $-52.78K | $-1.93M |
| Gross Profit Ratio | 0.00% | -421.00% | 100.00% | -567.90% | -339.80% | -235.10% | -127.40% | -349.40% | -1602.60% | -2460.00% | -420.70% | -33.80% | -42.80% | -4.20% | -16.50% | -200.94% | 65.29% | 96.07% | -6.12% | 0.00% |
| Research and Development Expenses | $1.69M | $947.23K | $778.90K | $2.23M | $1.91M | $1.64M | $1.80M | $6.44M | $4.76M | $5.31M | $3.14M | $2.19M | $1.71M | $463.22K | $284.38K | $1.25M | $892.99K | $1.40M | $838.97K | $- |
| General and Administrative Expenses | $1.08M | $1.19M | $1.37M | $1.44M | $1.23M | $1.14M | $1.55M | $1.19M | $1.69M | $1.95M | $2.27M | $1.45M | $16.37M | $393.91K | $490.47K | $256.45K | $339.42K | $281.35K | $277.69K | $- |
| Selling and Marketing Expenses | $- | $- | $- | $2 | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Selling General and Administrative Expenses | $1.08M | $1.19M | $1.37M | $1.44M | $1.23M | $1.14M | $1.55M | $1.19M | $1.69M | $1.95M | $2.27M | $1.45M | $16.37M | $393.91K | $490.47K | $256.45K | $339.42K | $281.35K | $277.69K | $- |
| Other Expenses | $- | $- | $-25.53K | $-7.96K | $6.93K | $11.03K | $-789.63K | $-1.43M | $-279.35K | $-207.47K | $-603.10K | $-8.03M | $212.14K | $-444.52K | $-250.58K | $-416.49K | $2.17M | $-1.82M | $- | $- |
| Operating Expenses | $2.77M | $2.14M | $2.15M | $3.67M | $2.71M | $2.29M | $2.56M | $6.20M | $6.16M | $7.06M | $4.80M | $2.01M | $16.89M | $412.62K | $524.27K | $1.09M | $404.77K | $-139.08K | $717.03K | $-3.33M |
| Cost and Expenses | $-644.75K | $2.14M | $2.15M | $3.67M | $2.71M | $2.29M | $2.56M | $6.20M | $6.16M | $7.06M | $4.80M | $2.01M | $16.89M | $412.62K | $524.27K | $1.09M | $404.77K | $-139.08K | $915.18K | $-1.40M |
| Interest Income | $- | $- | $- | $- | $- | $- | $1.50K | $70.88K | $1.12M | $- | $- | $- | $- | $- | $- | $293 | $1.84K | $77.56K | $639.95K | $752.35K |
| Interest Expense | $4.06K | $27.56K | $1.25M | $344.80K | $7.65K | $- | $1.50K | $51.86K | $4.86K | $37.78K | $15.02K | $1.43M | $524.82K | $910.33K | $347.83K | $247.97K | $216.17K | $201.72K | $- | $- |
| Depreciation and Amortization | $21.08K | $- | $1.84M | $3.16M | $2.71M | $2.29M | $2.56M | $38 | $38 | $38 | $38 | $-8.02M | $50 | $50 | $51 | $52 | $49 | $50 | $50 | $- |
| EBITDA | $665.83K | $-1.94M | $- | $-3.16M | $-2.68M | $-2.24M | $-2.56M | $-6.20M | $-9.85M | $-7.89M | $-935.90K | $-8.60M | $-16.89M | $-47.23K | $-524.22K | $-1.09M | $-404.73K | $139.13K | $-275.23K | $-1.22M |
| EBITDA Ratio | 0.00% | -1075.62% | -602.82% | -614.26% | -620.24% | -465.45% | -305.12% | -432.57% | -3983.94% | -3441.97% | -336.21% | -122.71% | -1430.26% | -92.81% | -209.21% | -523.80% | 213.47% | 7.62% | -106.12% | 0.00% |
| Operating Income | $644.75K | $-1.96M | $-1.84M | $-3.16M | $-2.71M | $-2.29M | $-2.56M | $-6.20M | $-6.16M | $-7.06M | $-4.80M | $-2.01M | $-16.89M | $-412.62K | $-524.27K | $-1.09M | $-404.77K | $139.08K | $-915.18K | $-1.93M |
| Operating Income Ratio | 0.00% | -1075.62% | -602.82% | -612.72% | -621.83% | -467.70% | -324.36% | -432.57% | -2206.30% | -3400.56% | -796.36% | -122.71% | -1406.28% | -92.82% | -209.23% | -262.51% | -48.91% | 7.62% | -106.12% | 0.00% |
| Total Other Income Expenses Net | $17.02K | $-12.35K | $-1.27M | $-348.68K | $16.51K | $54.65K | $369.43K | $722.71K | $-3.69M | $-867.94K | $3.85M | $-8.03M | $-312.68K | $-544.99K | $-387.42K | $1.11M | $1.96M | $-845.55K | $639.95K | $709.87K |
| Income Before Tax | $661.77K | $-1.97M | $-3.12M | $-3.50M | $-2.69M | $-2.24M | $-2.19M | $-5.48M | $-9.86M | $-7.92M | $-950.92K | $-10.04M | $-17.20M | $-957.61K | $-911.69K | $18.34K | $1.55M | $-706.47K | $-275.23K | $-1.22M |
| Income Before Tax Ratio | 0.00% | -1082.41% | -1019.41% | -680.42% | -618.04% | -456.56% | -277.57% | -382.16% | -3528.02% | -3818.90% | -157.67% | -613.78% | -1432.32% | -215.43% | -363.84% | 4.40% | 187.34% | -38.72% | -31.91% | 0.00% |
| Income Tax Expense | $- | $- | $-74 | $360.48K | $6.41K | $-3.33K | $-363.56K | $-2.91M | $3.67M | $906.33K | $-3.87M | $8.02M | $200.85K | $888.26K | $61.28K | $-1.04M | $504.24K | $-693.86K | $-74.62K | $-99.31K |
| Net Income | $661.77K | $-1.97M | $-3.12M | $-3.50M | $-2.69M | $-2.24M | $-1.83M | $-2.57M | $-13.52M | $-8.83M | $2.92M | $-10.04M | $-17.16M | $-935.54K | $-907.73K | $214.00K | $1.57M | $-704.50K | $-349.85K | $-662.61K |
| Net Income Ratio | 0.00% | -1082.41% | -1019.39% | -680.40% | -617.75% | -455.88% | -231.53% | -179.01% | -4840.31% | -4255.75% | 483.47% | -613.78% | -1429.32% | -210.46% | -362.26% | 51.38% | 189.76% | -38.61% | -40.57% | 0.00% |
| EPS | $0.07 | $-0.22 | $-0.55 | $-1.55 | $-0.87 | $-0.98 | $-1.73 | $-8.46 | $-84.13 | $-62.35 | $25.65 | $-100.00 | $-169.83 | $-13.99 | $-14.40 | $3.26 | $23.90 | $-10.72 | $-0.05 | $-0.11 |
| EPS Diluted | $0.07 | $-0.22 | $-0.55 | $-1.55 | $-0.87 | $-0.98 | $-1.73 | $-8.46 | $-84.13 | $-62.35 | $25.65 | $-100.00 | $-169.82 | $-13.99 | $-13.76 | $2.75 | $21.60 | $-10.72 | $-0.05 | $-0.11 |
| Weighted Average Shares Outstanding | 9.89M | 8.82M | 5.69M | 2.26M | 3.09M | 2.27M | 1.05M | 303.17K | 160.72K | 141.60K | 113.70K | 100.37K | 101.06K | 66.89K | 63.04K | 77.85K | 70.21K | 65.70K | 6.38M | 6.08M |
| Weighted Average Shares Outstanding Diluted | 9.89M | 8.82M | 5.69M | 2.26M | 3.09M | 2.27M | 1.05M | 303.17K | 160.73K | 141.62K | 113.70K | 100.37K | 101.07K | 66.89K | 65.98K | 78.02K | 72.71K | 65.70K | 6.38M | 6.08M |
| SEC Filing | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source |
Annual Balance Sheet
| Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Cash and Cash Equivalents | $3.50T | $1.12M | $3.15M | $12.26M | $194.21K |
| Short Term Investments | $- | $- | $- | $- | $- |
| Cash and Short Term Investments | $3.50T | $1.12M | $3.15M | $12.26M | $194.21K |
| Net Receivables | $124.11B | $97.56K | $276.82K | $441.72K | $- |
| Inventory | $- | $- | $-276.82K | $-441.72K | $- |
| Other Current Assets | $1.72T | $1.07M | $1.87M | $2.96M | $153.66K |
| Total Current Assets | $5.34T | $2.29M | $5.30M | $15.66M | $347.88K |
| Property Plant Equipment Net | $- | $- | $27.16K | $24.72B | $151 |
| Goodwill | $- | $- | $- | $- | $- |
| Intangible Assets | $- | $- | $- | $- | $- |
| Goodwill and Intangible Assets | $- | $- | $- | $- | $- |
| Long Term Investments | $- | $- | $- | $- | $- |
| Tax Assets | $- | $- | $- | $- | $- |
| Other Non-Current Assets | $252.55B | $419.22K | $558.72K | $-24.72B | $3.78K |
| Total Non-Current Assets | $252.55B | $419.22K | $585.88K | $754.76K | $3.93K |
| Other Assets | $- | $- | $- | $- | $- |
| Total Assets | $5.60T | $2.71M | $5.89M | $16.42M | $351.81K |
| Account Payables | $1.36T | $1.94M | $2.94M | $301.10K | $1.72M |
| Short Term Debt | $301.66B | $854.70K | $4.29M | $12.77M | $4.27M |
| Tax Payables | $- | $- | $- | $- | $- |
| Deferred Revenue | $- | $- | $- | $- | $159.05K |
| Other Current Liabilities | $548.46B | $542.26K | $2.23M | $3.41M | $856.01K |
| Total Current Liabilities | $2.21T | $3.33M | $9.46M | $16.48M | $7.01M |
| Long Term Debt | $- | $- | $140.15K | $4.44M | $- |
| Deferred Revenue Non-Current | $- | $- | $- | $- | $6.75M |
| Deferred Tax Liabilities Non-Current | $- | $- | $- | $- | $- |
| Other Non-Current Liabilities | $- | $26.39K | $310.35K | $3.65M | $- |
| Total Non-Current Liabilities | $- | $26.39K | $450.49K | $8.09M | $6.75M |
| Other Liabilities | $- | $- | $- | $- | $-6.75M |
| Total Liabilities | $10.10B | $3.36M | $9.91M | $24.58M | $7.01M |
| Preferred Stock | $- | $- | $- | $- | $1 |
| Common Stock | $136.00M | $315 | $642 | $2.46K | $1.58K |
| Retained Earnings | $-129.54T | $-121.56M | $-110.93M | $-85.85M | $-55.96M |
| Accumulated Other Comprehensive Income Loss | $- | $- | $- | $- | $0 |
| Other Total Stockholders Equity | $133.25T | $121.23M | $107.22M | $77.96M | $49.52M |
| Total Stockholders Equity | $3.71T | $-322.86K | $-4.03M | $-8.16M | $-6.44M |
| Total Equity | $3.38T | $-651.27K | $-4.34M | $-8.44M | $-6.66M |
| Total Liabilities and Stockholders Equity | $5.60T | $2.71M | $5.89M | $16.42M | $351.81K |
| Minority Interest | $-328.48B | $-328.41K | $-315.21K | $-279.81K | $-217.62K |
| Total Liabilities and Total Equity | $5.60T | $2.71M | $5.89M | $16.42M | $351.81K |
| Total Investments | $- | $- | $- | $- | $- |
| Total Debt | $301.66B | $854.70K | $4.41M | $12.75M | $4.27M |
| Net Debt | $-3.20T | $-268.91K | $1.26M | $483.42K | $4.08M |
Balance Sheet Charts
| Breakdown | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 | December 31, 2019 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and Cash Equivalents | $4.15M | $1.04M | $3.40M | $1.12M | $1.46M | $3.83M | $1.42M | $3.15M | $4.50M | $3.73M | $8.44M | $12.26M | $6.85M | $8.01M | $18.03K | $194.21K | $53.49K | $123.88K | $-341.54K | $1.06M |
| Short Term Investments | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $12.69M | $12.63M | $13.19M | $13.23M | $683.07K | $195.31M |
| Cash and Short Term Investments | $4.15M | $1.04M | $3.40M | $1.12M | $1.46M | $3.83M | $1.42M | $3.15M | $4.50M | $3.73M | $8.44M | $12.26M | $6.85M | $8.01M | $18.03K | $194.21K | $13.24M | $13.35M | $341.54K | $196.37M |
| Net Receivables | $1.78M | $224.22K | $96.22K | $97.56K | $107.74K | $107.58K | $289.31K | $276.82K | $140.81K | $276.63K | $808.60K | $441.72K | $86.87K | $75.35K | $- | $- | $- | $- | $- | $- |
| Inventory | $- | $- | $- | $-97.56K | $1.17M | $- | $- | $-276.82K | $1 | $1 | $- | $-441.72K | $1 | $- | $- | $- | $- | $- | $- | $- |
| Other Current Assets | $3.15M | $1.19M | $1.20M | $1.07M | $1.78M | $1.92M | $1.67M | $1.87M | $3.02M | $3.18M | $2.41M | $2.96M | $1.99M | $270.93K | $210.18K | $153.66K | $48.33K | $62.45K | $- | $138.57K |
| Total Current Assets | $9.09M | $2.46M | $4.70M | $2.29M | $2.76M | $5.86M | $3.37M | $5.30M | $7.66M | $7.19M | $11.66M | $15.66M | $8.92M | $8.36M | $228.21K | $347.88K | $101.82K | $186.33K | $341.54K | $1.20M |
| Property Plant Equipment Net | $- | $- | $- | $- | $2.72K | $10.87K | $19.02K | $27.16K | $35.31K | $10.25K | $17.61K | $24.72B | $31.54B | $50 | $100 | $151 | $- | $- | $- | $- |
| Goodwill | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Intangible Assets | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Goodwill and Intangible Assets | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $-3.88K | $- | $- | $- | $- | $- |
| Long Term Investments | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $12.69M | $12.63M | $- | $- | $- | $- |
| Tax Assets | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $61.28K | $- | $- | $- | $- | $- |
| Other Non-Current Assets | $294.22K | $335.88K | $377.55K | $419.22K | $458.17K | $491.68K | $525.20K | $558.72K | $592.24K | $743.99K | $695.48K | $-24.72B | $-31.54B | $838.09K | $3.78K | $-12.62M | $13.19M | $13.23M | $-341.54K | $195.31M |
| Total Non-Current Assets | $294.22K | $335.88K | $377.55K | $419.22K | $460.88K | $502.55K | $544.22K | $585.88K | $627.55K | $754.24K | $713.09K | $754.76K | $796.42K | $838.14K | $12.75M | $3.93K | $13.19M | $13.23M | $-341.54K | $195.31M |
| Other Assets | $- | $- | $1 | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $61.60M | $- |
| Total Assets | $9.38M | $2.80M | $5.07M | $2.71M | $3.22M | $6.36M | $3.91M | $5.89M | $8.29M | $7.95M | $12.37M | $16.42M | $9.72M | $9.20M | $12.98M | $351.81K | $13.29M | $13.41M | $61.60M | $196.51M |
| Account Payables | $1.97M | $481.97K | $981.72K | $1.94M | $916.42K | $1.27M | $1.60M | $2.94M | $1.29M | $3.05M | $959.63K | $301.10K | $471.86K | $3.14M | $2.23M | $1.72M | $- | $- | $- | $- |
| Short Term Debt | $387.18K | $454.46K | $245.97K | $854.70K | $356.40K | $467.59K | $38.24K | $4.29M | $7.62M | $2.53M | $6.09M | $12.77M | $2.83M | $476.25K | $17.85K | $4.27M | $- | $- | $- | $- |
| Tax Payables | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $19.78K | $19.78K | $125.68K | $629.91K | $63.95K | $138.57K |
| Deferred Revenue | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $24.87K | $- | $- | $-6.76M | $159.05K | $- | $- | $- | $- |
| Other Current Liabilities | $447.04K | $370.19K | $408.44K | $542.26K | $757.73K | $774.90K | $2.34M | $2.23M | $3.00M | $2.67M | $1.75M | $3.41M | $3.73M | $411.94K | $-1.95M | $995.27K | $326.43K | $163.69K | $3.43M | $2.63M |
| Total Current Liabilities | $2.80M | $1.31M | $1.64M | $3.33M | $2.03M | $2.52M | $3.98M | $9.46M | $11.91M | $8.25M | $8.80M | $16.48M | $7.03M | $4.03M | $319.18K | $7.01M | $452.10K | $793.60K | $3.49M | $2.77M |
| Long Term Debt | $- | $- | $- | $- | $- | $- | $- | $140.15K | $1.39M | $137.32K | $1.59M | $4.44M | $2.11M | $- | $- | $- | $- | $- | $- | $- |
| Deferred Revenue Non-Current | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $6.75M | $- | $- | $- | $- |
| Deferred Tax Liabilities Non-Current | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $-7.54M | $- | $- | $- | $- |
| Other Non-Current Liabilities | $3.21K | $9.62K | $17.43K | $26.39K | $30.47K | $47.70K | $91.32K | $310.35K | $1.41M | $360.80K | $871.41K | $3.65M | $957.10K | $- | $10.77M | $- | $7.57M | $7.57M | $48.57M | $566.27K |
| Total Non-Current Liabilities | $3.21K | $9.62K | $17.43K | $26.39K | $30.47K | $47.70K | $91.32K | $450.49K | $2.80M | $498.11K | $2.46M | $8.09M | $3.07M | $- | $10.77M | $7.54M | $7.57M | $7.57M | $48.57M | $7.57M |
| Other Liabilities | $- | $- | $- | $1 | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $-7.54M | $- | $- | $- | $- |
| Total Liabilities | $2.80M | $1.32M | $1.65M | $3.36M | $2.06M | $2.56M | $4.07M | $9.91M | $14.71M | $8.75M | $11.26M | $24.58M | $10.10M | $4.03M | $11.09M | $7.01M | $8.02M | $8.36M | $52.06M | $10.34M |
| Preferred Stock | $- | $- | $- | $- | $- | $- | $0 | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Common Stock | $1.39K | $815 | $733 | $315 | $287 | $267 | $128 | $642 | $221 | $3.55K | $3.00K | $2.46K | $2.42K | $2.42K | $622 | $1.58K | $271.00K | $52.18K | $4.54M | $181.17M |
| Retained Earnings | $-125.98M | $-126.64M | $-124.67M | $-121.56M | $-118.05M | $-115.36M | $-113.13M | $-110.93M | $-105.41M | $-95.51M | $-87.51M | $-85.85M | $-75.01M | $-57.84M | $-2.92M | $-55.96M | $4.94M | $4.72M | $2.11M | $2.46M |
| Accumulated Other Comprehensive Income Loss | $- | $- | $- | $- | $- | $- | $-0 | $- | $- | $- | $- | $- | $- | $- | $0 | $- | $- | $- | $-6.68M | $- |
| Other Total Stockholders Equity | $132.89M | $128.45M | $128.42M | $121.23M | $119.54M | $119.48M | $113.29M | $107.22M | $99.31M | $95.02M | $88.90M | $77.96M | $74.90M | $63.25M | $4.81M | $49.52M | $-206.99K | $230.65K | $-2.11M | $-178.63M |
| Total Stockholders Equity | $6.91M | $1.81M | $3.75M | $-651.27K | $1.49M | $4.12M | $166.72K | $-4.03M | $-6.09M | $-491.64K | $1.39M | $-8.16M | $-105.69K | $5.41M | $1.89M | $-6.44M | $5.00M | $5.00M | $-6.68M | $5.00M |
| Total Equity | $6.58M | $1.48M | $3.42M | $-979.68K | $1.16M | $3.79M | $-152.42K | $-4.34M | $-6.42M | $-797.58K | $1.11M | $-8.44M | $-385.29K | $5.17M | $1.67M | $-6.66M | $5.00M | $5.00M | $-6.68M | $5.00M |
| Total Liabilities and Stockholders Equity | $9.38M | $2.80M | $5.07M | $2.71M | $3.22M | $6.36M | $3.91M | $5.89M | $8.29M | $7.95M | $12.37M | $16.42M | $9.72M | $9.20M | $12.98M | $351.81K | $13.29M | $13.41M | $-6.68M | $15.34M |
| Minority Interest | $-328.48K | $-328.48K | $-328.48K | $-328.41K | $-327.44K | $-326.21K | $-319.15K | $-315.21K | $-327.43K | $-305.94K | $-279.63K | $-279.81K | $-279.60K | $-243.65K | $-221.59K | $-217.62K | $- | $- | $- | $- |
| Total Liabilities and Total Equity | $9.38M | $2.80M | $5.07M | $2.71M | $3.22M | $6.36M | $3.91M | $5.89M | $8.29M | $7.95M | $12.37M | $16.42M | $9.72M | $9.20M | $12.98M | $351.81K | $13.29M | $13.41M | $-6.68M | $15.34M |
| Total Investments | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $12.69M | $12.63M | $13.19M | $13.23M | $683.07K | $195.31M |
| Total Debt | $387.18K | $454.46K | $241.20K | $854.70K | $353.66K | $456.66K | $19.12K | $4.41M | $8.98M | $2.67M | $7.68M | $12.75M | $4.94M | $476.25K | $460.00K | $4.27M | $- | $- | $- | $- |
| Net Debt | $-3.77M | $-588.77K | $-3.16M | $-268.91K | $-1.11M | $-3.37M | $-1.40M | $1.26M | $4.47M | $-1.07M | $-763.28K | $483.42K | $-1.90M | $-7.54M | $441.97K | $4.08M | $-53.49K | $-123.88K | $341.54K | $-1.06M |
Annual Cash Flow
| Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Net Income | $-7.99T | $-10.63M | $-24.21M | $-29.15M | $-160.88K |
| Depreciation and Amortization | $1.20T | $- | $- | $151 | $201 |
| Deferred Income Tax | $- | $- | $- | $14.60M | $-2.45M |
| Stock Based Compensation | $110.72B | $879.16K | $1.07M | $121.76K | $178.68K |
| Change in Working Capital | $- | $-947.08K | $5.48M | $-1.30M | $185.10K |
| Accounts Receivables | $- | $179.26K | $164.90K | $-441.72K | $173.55K |
| Inventory | $- | $- | $-164.90K | $441.72K | $-173.55K |
| Accounts Payables | $-578.93B | $-1.23M | $2.64M | $-1.42M | $1.18M |
| Other Working Capital | $- | $107.95K | $2.84M | $120.00K | $-998.72K |
| Other Non Cash Items | $-823.61B | $-85.79K | $-233.42K | $7.49M | $997.46K |
| Net Cash Provided by Operating Activities | $-7.50T | $-10.78M | $-17.89M | $-8.24M | $-1.25M |
| Investments in Property Plant and Equipment | $- | $2 | $- | $- | $- |
| Acquisitions Net | $- | $- | $4.50K | $- | $- |
| Purchases of Investments | $- | $- | $- | $- | $- |
| Sales Maturities of Investments | $- | $- | $- | $- | $- |
| Other Investing Activities | $- | $- | $4.50K | $- | $183.40M |
| Net Cash Used for Investing Activities | $- | $- | $4.50K | $- | $183.40M |
| Debt Repayment | $- | $605.43K | $6.13M | $13.91M | $1.10M |
| Common Stock Issued | $- | $9.05M | $3.78M | $6.63M | $- |
| Common Stock Repurchased | $- | $- | $- | $- | $- |
| Dividends Paid | $-290.00M | $- | $-913.20K | $-803.14B | $- |
| Other Financing Activities | $9.88T | $-899.55K | $3.55M | $-225.68K | $20 |
| Net Cash Used Provided by Financing Activities | $9.88T | $8.76M | $8.77M | $20.31M | $1.10M |
| Effect of Forex Changes on Cash | $- | $- | $- | $- | $-183.40M |
| Net Change in Cash | $2.38T | $-2.02M | $-9.12M | $12.07M | $-147.32K |
| Cash at End of Period | $3.50T | $1.12M | $3.15M | $12.26M | $194.21K |
| Cash at Beginning of Period | $1.12T | $3.15M | $12.26M | $194.21K | $341.54K |
| Operating Cash Flow | $-7.50T | $-10.78M | $-17.89M | $-8.24M | $-1.25M |
| Capital Expenditure | $- | $2 | $- | $- | $- |
| Free Cash Flow | $-7.50T | $-10.78M | $-17.89M | $-8.24M | $-1.25M |
Cash Flow Charts
| Breakdown | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 | December 31, 2019 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | $661.77K | $-1.97M | $-3.12M | $-3.50M | $-2.69M | $-2.24M | $-2.19M | $-5.48M | $-9.86M | $-7.92M | $-950.92K | $-10.04M | $-17.20M | $-997.61K | $-911.69K | $18.34K | $1.55M | $-704.50K | $-1.02M | $-1.32M |
| Depreciation and Amortization | $- | $- | $1.17M | $326.15K | $- | $- | $- | $- | $- | $- | $- | $-151 | $50 | $50 | $51 | $52 | $49 | $50 | $50 | $- |
| Deferred Income Tax | $- | $- | $- | $-476.71K | $- | $- | $- | $- | $- | $- | $- | $2.38M | $12.54M | $-365.33K | $-61.28K | $-1.36M | $-2.17M | $- | $- | $110 |
| Stock Based Compensation | $20.82K | $26.55K | $33.21K | $628.94K | $55.67K | $77.42K | $117.13K | $216.68K | $157.15K | $295.58K | $402.43K | $16.74K | $24.83K | $36.37K | $43.82K | $58.62K | $51.51K | $36.06K | $32.49K | $- |
| Change in Working Capital | $-1.70M | $-388.39K | $-1.51M | $742.00K | $382.11K | $-902.99K | $-1.17M | $2.75M | $-568.20K | $2.34M | $959.94K | $-1.78M | $229.56K | $284.47K | $-36.16K | $498.84K | $200.30K | $-1.11M | $-230.63K | $87.69K |
| Accounts Receivables | $126.66K | $-128.00K | $1.34K | $-169.24K | $-160 | $181.73K | $-12.49K | $-136.01K | $135.82K | $531.97K | $-366.88K | $-354.85K | $-11.51K | $-75.35K | $- | $- | $- | $139.31K | $34.24K | $- |
| Inventory | $- | $- | $- | $1.34M | $160 | $-181.73K | $-1.16M | $136.01K | $-135.82K | $-531.97K | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Accounts Payables | $1.74M | $-499.75K | $-1.30M | $793.09K | $-358.21K | $-323.54K | $-1.35M | $1.66M | $-1.76M | $2.09M | $658.53K | $-170.75K | $-1.60M | $439.60K | $-92.18K | $22.29K | $334.96K | $- | $723.17K | $2.43M |
| Other Working Capital | $-3.56M | $239.35K | $-220.52K | $-1.22M | $740.32K | $-579.45K | $1.35M | $1.09M | $1.19M | $252.02K | $301.41K | $-1.61M | $1.83M | $-155.14K | $56.02K | $476.55K | $-134.66K | $-1.25M | $-264.88K | $-87.69K |
| Other Non Cash Items | $-2.34K | $19.75K | $2.52M | $482.12K | $-9.62K | $-43.67K | $-364.06K | $-783.89K | $3.55M | $846.62K | $-3.85M | $5.65M | $577.34K | $909.74K | $448.11K | $249.93K | $216.17K | $1.52M | $917.93K | $-808.27K |
| Net Cash Provided by Operating Activities | $-1.02M | $-2.31M | $-3.41M | $-1.80M | $-2.26M | $-3.11M | $-3.61M | $-3.30M | $-6.71M | $-4.44M | $-3.44M | $-3.77M | $-3.82M | $-132.31K | $-517.15K | $-533.86K | $-152.91K | $-257.15K | $-303.42K | $-2.04M |
| Investments in Property Plant and Equipment | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $3.69K | $-3.69K | $- | $- | $- |
| Acquisitions Net | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $4.50K | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Purchases of Investments | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $62.50K | $-62.50K | $- | $- | $- | $- | $- |
| Sales Maturities of Investments | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Investing Activities | $- | $- | $- | $- | $- | $- | $- | $4.50K | $- | $- | $4.50K | $- | $- | $- | $-62.50K | $48.78M | $- | $- | $134.62M | $11.70M |
| Net Cash Used for Investing Activities | $- | $- | $- | $- | $- | $- | $- | $4.50K | $- | $- | $4.50K | $- | $- | $62.50K | $-62.50K | $3.69K | $-3.69K | $- | $134.62M | $11.70M |
| Debt Repayment | $- | $- | $-638.87K | $1.61M | $- | $-584.86K | $-415.35K | $-1.14M | $7.53M | $-265.81K | $- | $8.98M | $4.03M | $50.00K | $350.00K | $- | $300.00K | $600.00K | $200.00K | $566.27K |
| Common Stock Issued | $1.67M | $- | $6.79M | $-9.05M | $- | $6.36M | $2.69M | $3.78M | $- | $- | $- | $1.18M | $-1.18M | $8.07M | $- | $- | $- | $- | $- | $- |
| Common Stock Repurchased | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $-11.58M |
| Dividends Paid | $- | $- | $-290 | $-4.63K | $- | $- | $- | $- | $- | $- | $-715.58K | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Financing Activities | $2.46M | $-51.23K | $6.33M | $-144.54K | $-102.45K | $-253.84K | $-398.72K | $-1.25M | $-51.17K | $- | $-391.27K | $207.03K | $-195.42K | $7.80M | $262.86K | $225.00K | $- | $20 | $-135.48M | $- |
| Net Cash Used Provided by Financing Activities | $4.13M | $-51.23K | $5.69M | $1.46M | $-102.45K | $5.52M | $1.87M | $1.94M | $7.48M | $-265.81K | $-391.27K | $9.19M | $2.66M | $7.85M | $612.86K | $-168.38K | $300.00K | $600.02K | $200.00K | $-11.02M |
| Effect of Forex Changes on Cash | $- | $- | $- | $- | $- | $- | $- | $-4.50K | $- | $- | $- | $- | $- | $- | $62.50K | $- | $- | $- | $- | $- |
| Net Change in Cash | $3.11M | $-2.36M | $2.28M | $-340.78K | $-2.37M | $2.41M | $-1.73M | $-1.36M | $768.43K | $-4.71M | $-3.82M | $5.42M | $-1.17M | $7.72M | $95.71K | $-530.17K | $143.40K | $342.87K | $-823.03K | $571.43K |
| Cash at End of Period | $4.15M | $1.04M | $3.40M | $1.12M | $1.46M | $3.83M | $1.42M | $3.15M | $4.50M | $3.73M | $8.44M | $12.26M | $6.85M | $8.01M | $289.93K | $194.21K | $724.38K | $580.98K | $238.12K | $1.06M |
| Cash at Beginning of Period | $1.04M | $3.40M | $1.12M | $1.46M | $3.83M | $1.42M | $3.15M | $4.50M | $3.73M | $8.44M | $12.26M | $6.85M | $8.01M | $289.93K | $194.21K | $724.38K | $580.98K | $238.12K | $1.06M | $489.72K |
| Operating Cash Flow | $-1.02M | $-2.31M | $-3.41M | $-1.80M | $-2.26M | $-3.11M | $-3.61M | $-3.30M | $-6.71M | $-4.44M | $-3.44M | $-3.77M | $-3.82M | $-132.31K | $-517.15K | $-533.86K | $-152.91K | $-257.15K | $-303.42K | $-2.04M |
| Capital Expenditure | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $3.69K | $-3.69K | $- | $- | $- |
| Free Cash Flow | $-1.02M | $-2.31M | $-3.41M | $-1.80M | $-2.26M | $-3.11M | $-3.61M | $-3.30M | $-6.71M | $-4.44M | $-3.44M | $-3.77M | $-3.82M | $-132.31K | $-517.15K | $-530.17K | $-156.60K | $-257.15K | $-303.42K | $-2.04M |
Ensysce Biosciences Stock Forecast
Analyst ratings, price targets, and earnings estimates for ENSC.
ENSC Analyst Ratings
Strong Buy
Based on 1 analysts in the past 3 months
Recent Price Targets
Recommendation Trends
Analyst Estimates
Revenue Estimates
Net Income Estimates
EPS Estimates
Revenue Estimates
Net Income Estimates
EPS Estimates
Revenue Estimates
Net Income Estimates
EPS Estimates
Latest Price Target Updates
| Date | Analyst | Firm | Price Target | Price When Posted | Upside |
|---|
Ensysce Biosciences Dividends
Explore Ensysce Biosciences's dividend history, including dividend yield, payout ratio, and historical payments.
Peers: Biotechnology
This section provides companies within the same sector, on the same exchange, and of similar market capitalization, allowing comparisons of key financial indicators among peers.
| Company | Market Cap | Price | EPS | P/E Ratio | P/B Ratio |
|---|---|---|---|---|---|
Zura Bio Limited
ZURA
|
$70.52M | $1.08 | $-1.83 | $-2.38 | $2.42 |
Phio Pharmaceuticals Corp.
PHIO
|
$6.35M | $1.33 | $-46.87 | $-0.15 | $0.20 |
Sonnet BioTherapeutics Holdings, Inc.
SONN
|
$4.05M | $1.32 | $-11.35 | $-0.59 | $-9.02 |
180 Life Sciences Corp.
ATNF
|
$3.43M | $1.08 | $-52.60 | $-0.08 | $-12.05 |
Cardio Diagnostics Holdings, Inc.
CDIO
|
$20.96M | $0.40 | $-0.66 | $-3.77 | $10.68 |
Virax Biolabs Group Limited
VRAX
|
$5.60M | $1.29 | $-3.36 | $-0.22 | $0.27 |
Blue Water Vaccines, Inc.
BWV
|
$3.41M | $0.18 | $-2.19 | $-3.62 | $2.31 |
Revelation Biosciences, Inc.
REVB
|
$2.96M | $3.27 | $-8768.31 | $0.00 | $0.00 |
Hillstream BioPharma, Inc.
HILS
|
$4.17M | $0.24 | $-7.14 | $-0.03 | $0.03 |
Kiora Pharmaceuticals, Inc.
KPRX
|
$9.75M | $3.25 | $-23.26 | $-0.20 | $0.41 |
Quoin Pharmaceuticals, Ltd.
QNRX
|
$1.49M | $0.30 | $-1911.50 | $0.00 | $0.00 |
Allarity Therapeutics, Inc.
ALLR
|
$4.00M | $0.90 | $-0.01 | $-55311.38 | $-239280.53 |
Kiromic BioPharma, Inc.
KRBP
|
$3.18M | $1.20 | $-1.03 | $-0.87 | $-1.86 |
Biodexa Pharmaceuticals Plc
BDRX
|
$2.89K | $1.99 | $-224.13 | $0.00 | $0.00 |
PaxMedica, Inc. Common Stock
PXMD
|
$2.18K | $0.00 | $-11.00 | $-0.07 | $0.37 |
Related Metrics
Explore detailed financial metrics and analysis for ENSC.